source
- Encoded Therapeutics secures $275M Series F to advance gene therapy for Dravet syndromeEncoded Therapeutics announced a $275 million Series F financing round aimed at moving its lead gene‑therapy candidate, ETX101, toward pivotal trials for Dravet syndrome. In the ongoing Phase 1/2…
- Drugmakers Rethink Launch Strategies as MFN Pricing Rules Shake MarketA new Numerof & Associates report says that the rollout of Most Favored Nation (MFN) pricing rules is forcing drugmakers to overhaul how they choose launch markets. Executives surveyed said the Un…